NJ Bio, Inc., will be participating in the AACR Annual Meeting, taking place from April 25–30, 2025, at McCormick Place Convention Center, Chicago, Illinois. AACR, the largest conference in cancer research, brings together scientists, clinicians and professionals across the globe to share and discuss the latest and most impactful breakthroughs in the field. Under the theme “Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact,” this year’s meeting promises to cover a broad range of key areas and showcase significant progress across the cancer research spectrum, providing an ideal platform to engage with the global research community and explore new avenues for collaboration.
NJ Bio will be exhibiting at booth #1563, highlighting cutting-edge trends in antibody-drug conjugates and their potential in targeted cancer therapies. With years of experience delivering contract research services to leading pharmaceutical companies and being recognized as the Best CRO for four consecutive years, NJ Bio stands as a trusted partner in ADC research and development. From early discovery and process optimization to manufacturing, NJ Bio supports clients throughout the entire ADC development lifecycle. Leveraging deep expertise in chemistry, the company tackles complex challenges at every stage, helping accelerate development programs and drive them toward clinical success. Through its recent strategic partnership with Suven Pharma, NJ Bio now offers a platform that extends all the way to manufacturing and commercialization.
The team looks forward to connecting with industry leaders, researchers, and potential partners to discuss how NJ Bio’s integrated chemistry solutions can accelerate the next generation of targeted cancer therapies.